

Pre Diagnostics AS – Company Introduction

*Pre Diagnostics AS is a Norwegian R&D-based biotech company developing patented diagnostic tests for dementia diseases. Currently 9 employees + consultants and active board members, Prof. Ole Petter Ottersen as executive chairman. Public research grants of MEUR 15 (including two EU projects) and MEUR 5 in form of equity from partners and “family office” investors have funded our “state of the art” laboratory facilities with a highly skilled team of engineers. CE-mark is obtained for PreADx - an **Alzheimer’s disease blood test** - the first phase of achieving our goal to build a leading dementia diagnostic company. Now the PreADx immunoassay is further developed into a **uniquely positioned ARIA biomarker system** representing the realm of personalized medicine.*



The new antibody-based Alzheimer’s disease drugs have serious side effects in a substantial proportion of the patients receiving them. The latest recommendations are calling for biomarkers that can help us distinguish between those patients that stand to benefit from the treatment and those patients that are at risk for serious side effects. Such a biomarker can safely be said to be a medical holy grail in this transformative moment of Alzheimer’s therapy as they would be critical for market penetration of the new drugs. Pre Diagnostics’ unique proprietary blood-based biomarkers hold a strong potential in this regard and the EU grant provides the funding for further development and clinical validation.

Professor Ole Petter Ottersen

Executive Chairman of Pre Diagnostics AS

FluiDx AD

A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of Alzheimer’s disease



Early detection: Key in fighting diseases

Early detection of disease will play a crucial role in AD, bringing unprecedented medical, societal and economic benefits. Early diagnosis can improve patient care and reduce public healthcare spending by billions of dollars. Pharmaceutical companies are dependant on diagnostic tools both for recruitment of the right patients for clinical studies, and for identifying a large number of patients now when their new drugs are becoming available in the market. To create reliable, affordable, and non-invasive fluid biomarkers for early detection and monitoring of patients is still considered “the holy grail” by scientists and industry, aiming at improving the quality of care of AD patients.

Pre Diagnostics: Very large market opportunity


The dementia diagnostics market is expected to become a high-growth market, where Pre Diagnostic’s technology has a strong margin potential. The company is building a unique “platform

THE LANCET

A Growing Health Crisis

The projected number of people with dementia, millions

■ High-income countries ■ Low- & middle-income countries




Source: Lancet, and Alzheimer’s Disease International


«We need to detect and diagnose Alzheimer’s earlier»

«A more reliable, affordable and accessible diagnostic - such as a blood test - would make it easier to see how Alzheimer’s progresses and track how effective new drugs are»

Bill Gates



Pre Diagnostics
Next generation
blood tests



technology” that has the makings of becoming a game-changer for future diagnostics and personalized medicine in neuroscience/dementia.

A unique and patented technology platform

R&D activities were conducted at a low scale until 2019, when the company obtained a substantial R&D grant from the EU’s prestigious Horizon 2020 program. Since then Pre Diagnostics has strengthened its capabilities with more scientists and new tailor-made laboratory facilities for further development and clinical validation of dementia diagnostics tests.

Selected recent accomplishments

2024 has been a productive year in terms of moving the technology towards market:

- Significant strengthening of the patent portfolio (ARIA)
- Commercial traction established
- Selected as partner and for AI-Mind, analysis of blood samples from 1.000 patients in our service laboratory
- EU grant MNOK 90 for our Alzheimer project FluidX-AD with outstanding European partners

Now PreDx is seeking industrial collaborator(s) to speed up the ARIA biomarker development.

We believe our unique ARIA biomarkers should offer strategic opportunities for the right industrial partner, since there is an urgent need for better diagnostic tools for drugs like *lecanemab* and *donanemab* to obtain widespread use.

Important Milestones going forward

- ARIA data to be presented for industrial partners (2025)
- Proof-of-concept for saliva as screening test AD (2026)
- Optimization AD-tests (EU-project tech part) (2025/26)
- Parkinson test proof-of-concept (2025)
- Commercial service lab (fluid samples, dementia) (2025)
- Clinical validation in EU project (FluidX-AD) (2026/27)
- Partnering/license agreement, ARIA test (2026/27)

International capital market advisory services

Pre Diagnostics is selected as a client by BTIG, a top-tier global financial services firm, headquartered in the US and highly specialized in Diagnostics and Device.

A BTIG healthcare analyst wrote to PreDx:

"I am very excited about all the diagnostic/ monitoring/personalized medicine opportunities in neurodegenerative diseases, and I think it's a great time to be a key player in the space right now."



PreDx SHAREHOLDER NEWSLETTER

Pre Diagnostics and Roche Diagnostics have been selected as diagnostic partners in large pan-European dementia project AI-Mind.

In AI-Mind PreDx has successfully performed analysis of blood samples from approximately 1.000 patients participating in the multi-site clinical study, an integral part of the AI-Mind project. This major task also creates the basis for establishing a PreDx commercial Nordic service laboratory in Oslo for dementia diagnostics. Furthermore, access to samples from the AI-Mind clinical study will also allow further clinical validation of Pre Diagnostics’ proprietary CE-marked AD tests for intracellular analysis of monocytes and the ARIA biomarker system. This is an excellent opportunity to build further clinical evidence for our AD biomarkers. In addition, with AI-Mind and FluidX-AD now PreDx has become a part of a broad international network of clinical and industrial partners.



Principal Investigator and Coordinator, **AI-Mind**, Professor Ira Hebold Haraldsen, MD, PhD commented:

"It is a big step forward in the AI-Mind project to welcome PreDx as a new partner in our consortium. Pre Diagnostics is not only the chosen partner and service laboratory for analysis of blood samples because of its cutting edge blood biomarkers portfolio in identifying pre-dementia stages, reaching from p-tau correlated ones to intracellular pathology representations by monocytes, but also the outlook to integrate Pre Diagnostics future products into our AI-Mind research and innovation portfolio is intriguing."

The Executive Management Team:



A team with 80 years of experience from the international biotech, diagnostics and pharma industries:

Håkon Sæterøy Co-founder & CEO

With 30 years of experience in management, corporate finance and business development, Sæterøy has an extensive international network. Sæterøy has been a co-founder and board member of several life science companies, including Nansen Neuroscience Network (Chair from 2010 – 2012) and Board Member of Oslo Cancer Cluster (2007 - 2014). Håkon is Chair of IC Targets AS and was Chair of listed diagnostic company DiaGenic ASA from 2002 – 2010, Chair of Serodus ASA from 2008 – 2012 and Chair/Board Member of Skannex AS from 2008 – 2014.

Erik Christensen Co-founder & CMO

Erik has extensive experience within blood-based diagnostics, as certified clinical pathologist at university hospitals and 10 years in Abbott Diagnostics, followed by 15 years executive management of companies with AD blood biomarkers. Experience in international pharma and diagnostic business across Europe, in the US and India. Successfully negotiated research & development contracts with large multinational companies like Pfizer and GE Healthcare, in addition to soft funded research programs for 100 mill NOK from EU and NRC. As CEO of DiaGenic ASA, he gained substantial experience with building a start-up diagnostic company. As an experienced laboratory professional manager he will be a board member of our new service laboratory.

Line Amundsen LABORATORY DIRECTOR

Line is a chemist with a Master's degree from The University of Bergen. Having spent many years working in an ISO-certified clinical laboratory at Haukeland University Hospital, Line has demonstrated commitment to precision and quality in her work with assay development and validation for clinical use. Beyond her contributions in a clinical laboratory, she has also honed her skills in the industry where she has further refined her knowledge and expertise in development and validation of immunoassays. Throughout her career she has gained significant experience in managing laboratory operations for both research and service purposes.

For more information and meeting requests, please contact:

Håkon Sæterøy, CEO Pre Diagnostics AS

Phone: +47 92695175

E-mail: Haakon@pre-diagnostics.com

State-of-the-art laboratory facilities:



The investment and partnering opportunities:

The company has raised a total financing of MNOK 225:

- Total raised equity of MNOK 60 (MNOK 12 in 2024)
- Before 2024: MNOK 70 raised in form of non-dilutive grants, of which MNOK 10 remaining for 2025
- 2024: Innovation Loan MNOK 5 from Innovation Norway
- 2024: MEUR 7,7 (MNOK 90) EU grant obtained for consortium led by PreDx – a 100% non-dilutive financing for optimization and clinical validation of our AD biomarkers.
- Approx. MNOK 35 of the EU grant goes directly to PreDx, first payment received January 2025

The combination of grants and new equity provides a satisfactory financial runway. "Use of proceeds" from next private placement will mainly be for further development of the Parkinson test and certification of our commercial service lab, plus commercial partnering activities:

- Industrial dialogues initiated
- Seeking industrial collaborators for first partnering agreement by 2026

Disclaimer:

The information in this document is published in good faith and for a limited audience to learn more about the company. We do not make any warranties about the completeness, reliability, and accuracy of this information. We reserve the right for any errors and omissions. Changes to the document may occur. Any action you take upon the information in this document is strictly at your own risk. The Company and/or advisors to the Company are not liable for any losses and/or damages in connection with the use of the information.